Elsevier

Drug and Alcohol Dependence

Volume 145, 1 December 2014, Pages 34-47
Drug and Alcohol Dependence

Review
What we know, and don’t know, about the impact of state policy and systems-level interventions on prescription drug overdose

https://doi.org/10.1016/j.drugalcdep.2014.10.001Get rights and content

Highlights

  • We review the impact of state policy and systems interventions on prescription drug overdose.

  • PDMPs, insurer efforts, legislation, guidelines, and naloxone distribution show promise.

  • Study quality is low; additional research can inform improvements in opioid prescribing and use.

Abstract

Background

Drug overdose deaths have been rising since the early 1990s and is the leading cause of injury death in the United States. Overdose from prescription opioids constitutes a large proportion of this burden. State policy and systems-level interventions have the potential to impact prescription drug misuse and overdose.

Methods

We searched the literature to identify evaluations of state policy or systems-level interventions using non-comparative, cross-sectional, before–after, time series, cohort, or comparison group designs or randomized/non-randomized trials. Eligible studies examined intervention effects on provider behavior, patient behavior, and health outcomes.

Results

Overall study quality is low, with a limited number of time-series or experimental designs. Knowledge and prescribing practices were measured more often than health outcomes (e.g., overdoses). Limitations include lack of baseline data and comparison groups, inadequate statistical testing, small sample sizes, self-reported outcomes, and short-term follow-up. Strategies that reduce inappropriate prescribing and use of multiple providers and focus on overdose response, such as prescription drug monitoring programs, insurer strategies, pain clinic legislation, clinical guidelines, and naloxone distribution programs, are promising. Evidence of improved health outcomes, particularly from safe storage and disposal strategies and patient education, is weak.

Conclusions

While important efforts are underway to affect prescriber and patient behavior, data on state policy and systems-level interventions are limited and inconsistent. Improving the evidence base is a critical need so states, regulatory agencies, and organizations can make informed choices about policies and practices that will improve prescribing and use, while protecting patient health.

Introduction

In 2011, drug overdose was the leading cause of injury death, reaching epidemic levels in the United States. Among deaths where the drugs involved were specified, three quarters (over 16,000) of prescription drug overdoses involved opioid analgesics (CDC, 2014). While effective in treating cancer pain (Wiffen et al., 2013) and acute pain, such as in the perioperative setting (American Society of Anesthesiologists Task Force on Acute Pain Management, 2012), the evidence that opioids are effective at treating chronic, non-cancer pain safely over time is limited in quantity and quality (Haroutiunian et al., 2012, Noble et al., 2010). There are risks to opioid use including dependence, withdrawal, and overdose (Inturrisi, 2002). Because of their euphoric properties, they are also a candidate for diversion for nonmedical use. Yet, opioids are commonly prescribed: In 2010, an estimated 20% of patients presenting to physician offices in the United States with pain symptoms or diagnoses were prescribed opioids (Daubresse et al., 2013).

More than 125,000 people have died from overdoses involving prescription opioids during 1999–2010, and the number of such deaths per year quadrupled during this time period (CDC, 2011). Interestingly, opioid sales have increased in lock step during this period (CDC, 2011). While prescribing of opioids has increased and prescribing of non-opioid pain medications (e.g., non-steroidal anti-inflammatory drugs; NSAID) has decreased, changes in patient-reported pain severity seem to be insufficient in explaining shifts in prescribing (CDC, 2011, Chang et al., 2014).

Although it is a complicated picture, many overdose deaths can be linked to prescriptions from medical providers. For example, in a study of drug overdose fatalities in North Carolina, nearly half filled a prescription for at least one of the drugs that contributed to their death within 60 days of dying (Hirsch et al., 2014). In a study of opioid analgesic overdoses in an employer-sponsored insurance claims database, one-quarter of nonfatal overdoses were daily users with a prescription, 43.5% were other (intermittent) users with a prescription, and 31% used the opioid without a prescription (Paulozzi et al., 2014).

Several factors increase risk for drug overdose at the individual, community, and systems level. Individuals at higher risk include men; 35–54 year olds; whites and American Indians/Alaskan Natives; individuals at lower incomes; patients with mental health conditions; and patients receiving a high daily dose, prescriptions from multiple prescribers/pharmacies, and opioids combined with benzodiazepines. At the community level, those living in rural areas and communities with higher levels of use of prescription drugs prone to abuse are at higher risk (Paulozzi, 2012). Factors at the systems level include payer (with Medicaid incurring a higher rate of opioid prescriptions and adverse events such as ED visits and neonatal abstinence syndrome compared to other payers; Creanga et al., 2012, Raofi and Schappert, 2006) and prescriber volume (with those at high prescribing rates accounting for a greater proportion of patient deaths; Dhalla et al., 2011).

States operate the major levers that control access to drugs through prescription origination points (such as physician practices, emergency departments, hospitals, and pharmacies), payment and reimbursement (such as through insurers and pharmacy benefit managers), and public education (such as through campaigns and community initiatives). Innovative state policy and systems-level preventive interventions have been proposed to address the problem of opioid analgesic overdose at a population level. Table 1 summarizes these interventions and explains the state role. We sought to understand the evidence available on the effectiveness of such interventions on intermediate outcomes, such as provider and patient behavior, as well as health outcomes, such as fatal and nonfatal overdose. Previous reviews have investigated specific interventions (e.g., PDMPs), but none have integrated the strategies within one comprehensive, broad-scoped review across multiple strategies—a unique focus of the current paper.

Section snippets

Data sources and searches

With the assistance of a librarian, MEDLINE was searched for research articles evaluating on state policy and systems-level interventions published from 1946 to 2014 with search terms including, but not limited to, “drug overdose”, “analgesics/opioid”, “health education”, “patient education”, “organizational policy”, “prescription”, “monitoring”, “guideline”, “legislation”, “insurer”, “formulary”, and “drug utilization review”, resulting in over 500 citations. Additional articles were

Results

Fig. 1 illustrates the number of studies reviewed by type of intervention, and the type of outcomes measured in the studies. There was substantial variation in the number of studies by intervention, with a greater number of studies found for PDMPs, naloxone education and distribution programs, and clinical guidelines than for insurer strategies, state legislation, safe storage and disposal, and provider/patient education. There also were large differences in the types of outcomes studied, with

Discussion

States have a variety of tools they can use with the potential for curbing the prescription drug overdose epidemic, particularly overdose due to opioid analgesics. Over the past several years, as the overdose epidemic has received increased attention, states have made astounding gains in prevention innovation. State and systems-level strategies have much promise for changing opioid prescribing, influencing patient misuse, and reducing nonfatal and fatal overdose from opioid analgesics.

Role of funding source

No funding was provided for this work beyond salary support.

Contributors

Tamara M. Haegerich served as the lead author and edited the manuscript. Tamara M. Haegerich, Leonard J. Paulozzi, Brian J. Manns, and Christopher M. Jones contributed to construction of the literature search, selection of articles, review of articles, summarization of evidence, construction of evidence tables, and generation of conclusions. All authors have read and approved the final version submitted to Drug and Alcohol Dependence.

Conflict of interest

No conflict declared.

Acknowledgments

We would like to thank Bill Thomas from the CDC Public Health Library and Information Center for assistance with the literature search and Noah Aleshire and Akshara Menon for their assistance in identifying state legislation. The conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the Food and Drug Administration.

References (115)

  • J. McCauley et al.

    Pilot of a brief, web-based educational intervention targeting safe storage and disposal of prescription opioids

    Addict. Behav.

    (2013)
  • L. McCracken et al.

    Training for general practitioners in opioid prescribing for chronic pain based on practice guidelines: a randomized pilot and feasibility trial

    J. Pain

    (2012)
  • L. Paulozzi

    Prescription drug overdoses: a review

    J. Saf. Res.

    (2012)
  • S. Sherman et al.

    The life they save may be mine: diffusion of overdose prevention information from a city sponsored programme

    Int. J. Drug Policy

    (2009)
  • S. Shoemaker et al.

    Effect of six managed care pharmacy tools: A review of the literature

    J. Manag. Care Pharm.

    (2010)
  • S. Albert et al.

    Project Lazarus: community-based overdose prevention in rural North Carolina

    Pain Med.

    (2011)
  • Practice guidelines for acute pain management in the perioperative setting: an updated report by the American society of anesthesiologists task force on acute pain management

    Anesthesiology

    (2012)
  • C. Banta-Green et al.

    Police officers’ and paramedics’ experiences with overdose and their knowledge and opinions of Washington state's drug overdose-naloxone-good samaritan law

    J. Urban Health

    (2013)
  • C. Banta-Green et al.

    Washington's 911 Good Samaritan Drug Overdose Law—Initial Evaluation Results

    (2011)
  • A. Bennett et al.

    Characteristics of an overdose prevention, response, and naloxone distribution program in Pittsburgh and Allegheny County, Pennsylvania

    J. Urban Health

    (2011)
  • S. Blake

    The effect of the Louisiana medicaid lock-in on prescription drug utilization and expenditure

    Drug Benefit Trends

    (1999)
  • J. Brady et al.

    Prescription drug monitoring and dispensing of prescription opioids

    Public Health Rep.

    (2014)
  • O. Branagan et al.

    Providing health education on accidental drug overdose

    Nurs. Times

    (2006)
  • Brandeis University Prescription Drug Monitoring Program Training and Technical Assistance Center, 2014. Mandating PDMP...
  • Brandeis University Prescription Drug Monitoring Program Training and Technical Assistance Center, 2014b. Prescription...
  • F. Brason et al.

    Project Lazarus: an innovative community response to prescription drug overdose

    N.C. Med. J.

    (2013)
  • Centers for Disease Control and Prevention

    Vital signs: overdoses of prescription opioid pain relievers—United States, 1999–2008

    MMWR

    (2011)
  • Centers for Disease Control and Prevention

    Patient Review and Restriction Programs: Lessons Learned From State Medicaid Programs

    (2013)
  • Centers for Disease Control and Prevention, 2014. CDC WONDER (Wide-Ranging Online Data for Epidemiologic Research)....
  • F. Chinn

    Medicaid recipient lock-in program: Hawaii's experience in six years

    Hawaii Med. J.

    (1985)
  • R. Chou et al.

    Opioid treatment guidelines: clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain

    J. Pain

    (2009)
  • S. Cochella et al.

    Provider detailing: an intervention to decrease prescription opioid deaths in Utah

    Pain Med.

    (2011)
  • Colburn, D., Coady, J., Ellis, A., Griffin, H., Tripp, M., 2008. Medicaid integrity report: Iowa Comprehensive Program...
  • K. Corson et al.

    Primary care clinician adherence to guidelines for the management of chronic musculoskeletal pain: results from the study of the effectiveness of a collaborative approach to pain

    Pain Med.

    (2011)
  • A. Creanga et al.

    Maternal drug use and its effect on neonates: a population-based study in Washington state

    Obstet. Gynecol.

    (2012)
  • M. Crozier et al.

    The eastern North Carolina opioid prescribers project: a model continuing medical education workshop

    J. Opioid Manag.

    (2010)
  • L. Curtis et al.

    Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States

    Health Serv. Res.

    (2006)
  • M. Daubresse et al.

    Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000–2010

    Med. Care

    (2013)
  • M. Daubresse et al.

    Impact of a drug utilization review program on high-risk use of prescription controlled substances

    Pharmacoepidemiol. Drug Saf.

    (2014)
  • J. DeRosier

    Pain Clinic Legislation in Louisiana. Promising Legal Responses to the Epidemic of Prescription Drug Overdoses in The United States, Atlanta, GA

    (2008)
  • I. Dhalla et al.

    Clustering of opioid prescribing and opioid-related mortality among family physicians in Ontario

    Can. Fam. Physician

    (2011)
  • M. Doe-Simkins et al.

    Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study

    BMC Public Health

    (2014)
  • M. Doe-Simkins et al.

    Saved by the nose: bystander-administered intranasal naloxone hydrochloride for opioid overdose

    Am. J. Public Health

    (2009)
  • C. Dormuth et al.

    Effect of a centralized prescription network on inappropriate prescriptions for opioid analgesics and benzodiazepines

    CMAJ

    (2012)
  • L. Enteen et al.

    Overdose prevention and naloxone prescription for opioid users in San Francisco

    J. Urban Health

    (2010)
  • L. Fang et al.

    Two-year outcomes of a randomized, family-based substance use prevention trial for Asian American adolescent girls

    Psychol. Addict. Behav.

    (2013)
  • Florida Medicaid, 2005. Medicaid prescribed drug spending control program initiatives: quarterly report January 1–March...
  • M. Forrester

    Ingestions of hydrocodone, carisoprodol, and alprazolam in combination reported to Texas poison centers

    J. Addict. Dis.

    (2011)
  • G. Franklin et al.

    Changes in opioid prescribing for chronic pain in Washington state

    J. Am. Board Fam. Med.

    (2013)
  • G. Franklin et al.

    Bending the prescription opioid dosing and mortality curves: impact of the Washington state opioid dosing guideline

    Am. J. Ind. Med.

    (2013)
  • Cited by (241)

    • Trends in Opioid Prescribing by General Dentists and Dental Specialists in the U.S., 2012–2019

      2022, American Journal of Preventive Medicine
      Citation Excerpt :

      Short-term exposure to opioids increases the risk for future or persistent opioid use and adverse opioid outcomes (e.g., misuse, abuse, morbidity, mortality).6–8 Risk mitigation strategies to reduce adverse opioid outcomes have been implemented at the federal, state, and local levels, targeting all opioid prescribers, including dentists.9 Examples include the 2014 Drug Enforcement Administration rescheduling of hydrocodone and 2016 Centers for Disease Control and Prevention (CDC) guidelines for pain management.2,10

    View all citing articles on Scopus
    View full text